Literature DB >> 15099204

Are N-glycolylneuraminic acid (Hanganutziu-Deicher) antigens important in pig-to-human xenotransplantation?

Yuko Miwa1, Takaaki Kobayashi, Takaharu Nagasaka, DaGe Liu, Ma Yu, Itsuo Yokoyama, Akemi Suzuki, Akimasa Nakao.   

Abstract

BACKGROUND: N-glycolylneuraminic acid (NeuGc) epitopes, so called Hanganutziu-Deicher (HD) antigens, which are widely expressed on endothelial cells of all mammals except humans, are considered to be potential targets for natural and elicited anti-nonGalalpha1-3 Gal (Gal) antibodies in humans. We previously reported that anti-NeuGc antibodies were not detected in healthy humans by enzyme-linked immunosorbent assay (ELISA) using NeuGc-GM3-coated plates, and no antibody production was observed in patients with a history of exposure to pig cells. However, a recent paper has revealed that (i) anti-NeuGc antibodies to porcine red blood cells (PRBC) are detectable in most healthy humans, and (ii) the majority of anti-nonGal antibodies are specific for NeuGc epitopes. The purpose of this study was to reassess whether NeuGc is important as an immunogenic nonGal epitope.
METHODS: The binding of antibodies to PRBC and porcine aortic endothelial cells (PAEC) was compared. Cells were treated with (i) alpha-galactosidase, and then (ii) neuraminidase, which digests sialic acids, including NeuGc epitopes. Cells were incubated with human pooled sera, and applied to flow cytometric analysis. After enzyme digestion, almost complete reduction of Gal and NeuGc expression was confirmed by GS-IB4 and HU/Ch2-7 (a chicken monoclonal antibody against HD antigens), respectively. Trypsin, which removes membrane glycoproteins, and endoglycoceramidase which cleaves glycolipids, were used for differentiating between NeuGc-containing glycoproteins and glycolipids.
RESULTS: Neuraminidase-treatment reduced the binding of immunoglobulin G (IgG) antibodies to PRBC; about half of the anti-nonGal IgG antibodies to PRBC were directed to NeuGc. In contrast, anti-nonGal antibodies to PAEC were not directed to NeuGc. Trypsin-treatment markedly reduced the expression of NeuGc only on PRBC. Endoglycoceramidase-treatment was followed by a greater reduction in NeuGc epitopes on PAEC than on PRBC. Most NeuGc on PRBC appeared to be linked to proteins, but most NeuGc on PAEC was expressed on glycolipids.
CONCLUSIONS: Carbohydrate structures on PRBC are different from those on PAEC. Healthy human sera contain anti-nonGal IgG antibodies to NeuGc expressed on PRBC, but not on PAEC. We speculate that anti-nonGal IgG antibodies to PRBC can recognize both NeuGc and protein, and this may be the reason why such antibodies have not been detected by ELISA. A definite conclusion about the immunogenicity of NeuGc has not been obtained. More sera from patients (not from non-human primates) sensitized with porcine cells or organs need to be studied. Copyright Blackwell Munksgaard, 2004

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15099204     DOI: 10.1111/j.1399-3089.2004.00126.x

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  30 in total

1.  Absence of Gal epitope prolongs survival of swine lungs in an ex vivo model of hyperacute rejection.

Authors:  Bao-Ngoc H Nguyen; Agnes M Azimzadeh; Carsten Schroeder; Thomas Buddensick; Tianshu Zhang; Amal Laaris; Megan Cochrane; Henk-Jan Schuurman; David H Sachs; James S Allan; Richard N Pierson
Journal:  Xenotransplantation       Date:  2011 Mar-Apr       Impact factor: 3.907

2.  Trial using pig cells with the H-D antigen knocked down.

Authors:  Aki Yamamoto; Kosuke Ikeda; Dandan Wang; Shino Nakatsu; Yuichi Takama; Takehisa Ueno; Hiroshi Nagashima; Akihiro Kondo; Masahiro Fukuzawa; Shuji Miyagawa
Journal:  Surg Today       Date:  2012-08-05       Impact factor: 2.549

3.  Potential impact of the non-human sialic acid N-glycolylneuraminic acid on transplant rejection risk.

Authors:  Vered Padler-Karavani; Ajit Varki
Journal:  Xenotransplantation       Date:  2011 Jan-Feb       Impact factor: 3.907

Review 4.  Clinical lung xenotransplantation--what donor genetic modifications may be necessary?

Authors:  David K C Cooper; Burcin Ekser; Christopher Burlak; Mohamed Ezzelarab; Hidetaka Hara; Leela Paris; A Joseph Tector; Carol Phelps; Agnes M Azimzadeh; David Ayares; Simon C Robson; Richard N Pierson
Journal:  Xenotransplantation       Date:  2012 May-Jun       Impact factor: 3.907

5.  Brief report: a new profile of terminal N-acetyllactosamines glycans on pig red blood cells and different expression of alpha-galactose on Sika deer red blood cells and nucleated cells.

Authors:  Yingxia Tan; Feng Gong; Subo Li; Shouping Ji; Yanping Lu; Hongwei Gao; Hua Xu; Yangpei Zhang
Journal:  Glycoconj J       Date:  2010-04-27       Impact factor: 2.916

6.  Initial in vitro studies on tissues and cells from GTKO/CD46/NeuGcKO pigs.

Authors:  Whayoung Lee; Hidetaka Hara; Mohamed B Ezzelarab; Hayato Iwase; Rita Bottino; Cassandra Long; Jagdeece Ramsoondar; David Ayares; David K C Cooper
Journal:  Xenotransplantation       Date:  2016-03-14       Impact factor: 3.907

7.  Analysis of the N-glycans of recombinant human Factor IX purified from transgenic pig milk.

Authors:  Geun-Cheol Gil; William H Velander; Kevin E Van Cott
Journal:  Glycobiology       Date:  2008-05-02       Impact factor: 4.313

8.  Development of a consensus protocol to quantify primate anti-non-Gal xenoreactive antibodies using pig aortic endothelial cells.

Authors:  Agnes M Azimzadeh; Guerard W Byrne; Mohamed Ezzelarab; Emily Welty; Gheorghe Braileanu; Xiangfei Cheng; Simon C Robson; Christopher G A McGregor; David K C Cooper; Richard N Pierson
Journal:  Xenotransplantation       Date:  2014-09-01       Impact factor: 3.907

Review 9.  Current status of pig kidney xenotransplantation.

Authors:  Hayato Iwase; Takaaki Kobayashi
Journal:  Int J Surg       Date:  2015-08-22       Impact factor: 6.071

Review 10.  Xenotransplantation: immunological hurdles and progress toward tolerance.

Authors:  Adam Griesemer; Kazuhiko Yamada; Megan Sykes
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.